Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
Executive Summary
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
You may also be interested in...
Gilead Maintains Optimistic Outlook For Yescarta Despite Slow Growth
Gilead projects roughly $200m in sales growth for its CAR-T product Yescarta, despite the drug’s modest $6m sequential growth during the fourth quarter. For 2019 overall sales, the company projects slight growth, if any.
Celgene Gives Reassurances That Key Products And Programs Remain On Track
Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.
Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off
Withdrawal of filing of CheckMate 227 data in patients with high tumor mutational burden (TMB) means another delay for Opdivo in first-line lung cancer.